NEW YORK (GenomeWeb) – Advanced Biological Laboratories has signed a software marketing agreement with Tute Genomics which lets the former sell access to Tute's platform in Europe, Africa, and parts of Asia.
Salt Lake City, Utah-based Tute launched its cloud-based interpretation engine last November. The s system, which is used for annotating and prioritizing genetic variants, is based on Annotate Variation, a well known open source program that was developed by Kai Wang, an assistant professor of psychiatry and preventative medicine at the University of Southern California and the company's president.
Reid Robison, Tute's CEO, said in a statement that the partnership with ABL and the broader distribution of his firm's platform should result in "greater sales growth going forward."
Also this week, ABL launched OncoChek, a new platform for managing and analyzing genomic data in the oncology space. According to the company, the newest member of its portfolio is derived from DeepChek, its existing software for next-generation sequence data analysis.
Furthermore, OncoChek pairs well with Tute's interpretation platform, according to Chalom Sayada, ABL's CEO.
"With the continuous pipeline of new features appearing in the Tute Genomics platform including a broad range of updated annotation content, and the capability to rapidly analyse whole genomes or whole exomes, there is a natural fit with our own OncoChek platform," he said. Combining the capabilities from both products, "should ease the work of laboratories and researchers by providing them with validated and professional tools that should bring new results compared with currently available products."